Arpraziquantel

PreclinicalSmall molecule

PPeter Steinmann

Arpraziquantel is one of 5 small molecule programs targeting Schistosomiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchistosomiasisActive, not recruiting

SchistosomiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Schistosomiasis

#DrugCompanyPhaseTrials

Biltricide

Bayer

Approved

7 2

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Artesunate

Ferrous Sulphate

1 5

Arpraziquantel

PPeter Steinmann

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schistosomiasis1 trial

Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study

Recruiting·PPeter Steinmann··NCT06698510·18,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Arpraziquantel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arpraziquantel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arpraziquantel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peter Steinmann company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeter Steinmann

Arpraziquantel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schistosomiasis1 trial

References

Drug Info

Quick Facts

Related News